Jeffrey Lieberman

Jeffrey Lieberman's AcademicInfluence.com Rankings

Jeffrey Lieberman

Biology

#1373

World Rank

#2310

Historical Rank

#696

USA Rank

biology Degrees

Download Badge

Biology

Why Is Jeffrey Lieberman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Jeffrey Alan Lieberman is an American psychiatrist who specializes in schizophrenia and related psychoses and their associated neuroscience and pharmacological treatment . He was principal investigator for CATIE, the largest and longest independent study ever funded by the United States National Institute of Mental Health to examine existing pharmacotherapies for schizophrenia. He was president of the American Psychiatric Association from May 2013 to May 2014.

(See a Problem?)

Jeffrey Lieberman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Biological Insights From 108 Schizophrenia-Associated Genetic Loci (2014) (6445)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. (2005) (5220)
Practice guideline for the treatment of patients with schizophrenia, second edition. (2004) (2151)
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs (2013) (2011)
Genome-wide association study identifies five new schizophrenia loci (2011) (1680)
Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. (1999) (1248)
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. (2005) (1193)
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III (2005) (1160)
A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (2016) (1125)
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. (2007) (1009)
Duration of psychosis and outcome in first-episode schizophrenia. (1992) (932)
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. (2000) (932)
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. (2006) (916)
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. (2006) (887)
Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. (1993) (877)
Physical health monitoring of patients with schizophrenia. (2004) (829)
How mental health care should change as a consequence of the COVID-19 pandemic (2020) (813)
Brain volume in first-episode schizophrenia (2006) (787)
Catching Up on Schizophrenia Natural History and Neurobiology (2000) (781)
Antipsychotic drug effects on brain morphology in first-episode psychosis. (2005) (752)
Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects (2016) (736)
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. (1999) (733)
Microduplications of 16p11.2 are Associated with Schizophrenia (2009) (685)
A national study of violent behavior in persons with schizophrenia. (2006) (683)
Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways (2015) (676)
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. (2003) (608)
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. (2001) (592)
Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. (1994) (573)
Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia (1990) (568)
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches (2001) (555)
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline (2006) (544)
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. (2002) (525)
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls (2005) (518)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012) (495)
Longitudinal study of brain morphology in first episode schizophrenia (2001) (489)
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. (2003) (483)
Implications for the neural basis of social cognition for the study of schizophrenia. (2003) (480)
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial (2006) (476)
Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. (1999) (472)
Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective (1999) (464)
Provocative tests with psychostimulant drugs in schizophrenia (2004) (463)
Time course and biologic correlates of treatment response in first-episode schizophrenia. (1993) (451)
Barriers to employment for people with schizophrenia. (2006) (450)
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. (2008) (419)
Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver (2013) (414)
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. (2003) (407)
Regional Gray Matter Growth, Sexual Dimorphism, and Cerebral Asymmetry in the Neonatal Brain (2007) (407)
Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. (1994) (396)
Imaging endogenous dopamine competition with [11C]raclopride in the human brain (1994) (391)
Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain (2001) (379)
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. (2007) (364)
Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. (2001) (356)
Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia (1993) (347)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (2013) (346)
Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity (1997) (343)
Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine (2003) (343)
Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia (2002) (337)
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. (2008) (322)
A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial (2004) (314)
Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. (1997) (314)
Depression in first-episode schizophrenia. (1993) (312)
Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. (1995) (312)
Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. (1992) (306)
Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. (2015) (304)
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. (2004) (303)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia (2005) (301)
Genomewide association for schizophrenia in the CATIE study: results of stage 1 (2008) (301)
International clinical practice guidelines for early psychosis (2005) (300)
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1 (2008) (288)
Apoptotic mechanisms and the synaptic pathology of schizophrenia (2006) (286)
Absence of regional hemispheric volume asymmetries in first-episode schizophrenia. (1994) (286)
The Effects of Clozapine on Tardive Dyskinesia (1991) (286)
Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder (2002) (282)
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. (2007) (280)
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. (2008) (277)
Shape analysis of brain ventricles using SPHARM (2001) (276)
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. (2006) (274)
Boundary and Medial Shape Analysis of the Hippocampus in Schizophrenia (2003) (274)
Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. (1997) (272)
Update on the clinical efficacy and side effects of clozapine. (1991) (271)
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. (2007) (267)
Measurement of Brain Metabolites by 1H Magnetic Resonance Spectroscopy in Patients with Schizophrenia: A Systematic Review and Meta-Analysis (2005) (260)
Psychosocial treatment for first-episode psychosis: a research update. (2005) (254)
Tardive dyskinesia: prevalence, incidence, and risk factors. (1988) (251)
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. (2006) (248)
Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine (1995) (246)
Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. (2009) (246)
Prospective study of tardive dyskinesia in the elderly: rates and risk factors. (1998) (242)
Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. (1992) (239)
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. (2002) (237)
Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients (1998) (233)
Clozapine: guidelines for clinical management. (1989) (232)
Deficits in auditory and visual context-dependent processing in schizophrenia: defining the pattern. (2000) (232)
Extrapyramidal side-effects of antipsychotics in a randomised trial (2008) (230)
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study (2008) (226)
Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. (2001) (225)
Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood (2007) (221)
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection (2008) (220)
Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. (1996) (220)
Integrating incidence and prevalence of tardive dyskinesia. (1986) (215)
Serotonergic basis of antipsychotic drug effects in schizophrenia (1998) (212)
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. (2001) (212)
Statistical shape analysis of neuroanatomical structures based on medial models (2003) (208)
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. (2008) (207)
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome (2005) (207)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. (2007) (207)
Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder (2015) (206)
Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. (2005) (205)
HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. (1990) (202)
Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. (1995) (201)
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol (2004) (199)
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol (2005) (199)
Shape versus Size: Improved Understanding of the Morphology of Brain Structures (2001) (198)
Dopamine Partial Agonists (2004) (197)
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. (2010) (197)
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function (2004) (196)
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. (2005) (194)
Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder (2002) (192)
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. (1995) (192)
Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. (2004) (190)
Psychobiologic Correlates of Treatment Response in Schizophrenia (1996) (190)
Relationship of cognition and psychopathology to functional impairment in schizophrenia. (2008) (188)
Apoptotic mechanisms in the pathophysiology of schizophrenia (2005) (185)
Electrophysiological Indices of Automatic and Controlled Auditory Information Processing in First-Episode, Recent-Onset and Chronic Schizophrenia (2006) (185)
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery (2014) (182)
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). (2011) (181)
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia (2008) (179)
Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia (1995) (178)
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. (2005) (178)
Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia (2009) (176)
Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol (2004) (176)
Prospective study of tardive dyskinesia incidence in the elderly. (1991) (175)
Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association (2002) (174)
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. (2007) (173)
Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. (1997) (173)
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. (2001) (172)
Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory (2000) (172)
Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective, and schizophreniform disorders (2003) (169)
A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia (2013) (168)
The prevalence of tardive dyskinesia. (1991) (167)
Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. (2011) (167)
Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study (2009) (167)
Effectiveness of switching antipsychotic medications. (2006) (166)
Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. (2010) (165)
Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia (1999) (162)
Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. (1992) (162)
Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia (2000) (160)
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs (2010) (160)
Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and Therapeutics (2006) (160)
Science and recovery in schizophrenia. (2008) (158)
Relationship between psychostimulant-induced "high" and dopamine transporter occupancy. (1996) (157)
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode (2006) (156)
A comprehensive analysis of 22q11 gene expression in the developing and adult brain (2003) (156)
Substance Use in Persons With Schizophrenia: Baseline Prevalence and Correlates From the NIMH CATIE Study (2006) (155)
Postictal and chronic psychoses in patients with temporal lobe epilepsy. (1995) (155)
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. (2005) (155)
A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia (2011) (154)
Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial (2005) (154)
Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. (2001) (152)
A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia (2009) (152)
Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. (1996) (151)
Genomewide Pharmacogenomic Analysis of Response to Treatment with Antipsychotics (2009) (150)
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. (2007) (148)
Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings (2014) (147)
Delayed detection of psychosis: causes, consequences, and effect on public health. (2000) (146)
Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia (2005) (146)
Evidence for the Risks and Consequences of Adolescent Cannabis Exposure. (2017) (145)
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic (2006) (144)
The Neurosteroid Allopregnanolone Is Reduced in Prefrontal Cortex in Alzheimer’s Disease (2006) (142)
CATIE and CUtLASS: can we handle the truth? (2008) (142)
Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles (2014) (141)
Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis (1999) (141)
Cognitive Development in Schizophrenia: Follow-Back from the First Episode (2006) (137)
Does clozapine cause tardive dyskinesia? (1993) (137)
Olanzapine and Clozapine Increase the GABAergic Neuroactive Steroid Allopregnanolone in Rodents (2003) (135)
The natural history and pathophysiology of treatment resistant schizophrenia. (1998) (135)
Neurochemistry and neuroendocrinology of schizophrenia: a selective review. (1993) (134)
Tardive dyskinesia: prevalence, incidence, and risk factors. (1988) (134)
Suicidal ideation and suicide attempts among adults with psychotic experiences: data from the Collaborative Psychiatric Epidemiology Surveys. (2015) (133)
Results of phase 3 of the CATIE schizophrenia trial (2009) (133)
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. (2017) (132)
Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia (2001) (132)
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. (2004) (130)
Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. (1988) (130)
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. (2013) (129)
The Mount Sinai conference on the pharmacotherapy of schizophrenia. (2002) (129)
What CATIE found: results from the schizophrenia trial. (2008) (127)
Olanzapine and haloperidol in first episode psychosis: Two-year data (2006) (127)
The Prevalence of Acute Extrapyramidal Signs and Symptoms in Patients Treated With Clozapine, Risperidone, and Conventional Antipsychotics (1998) (126)
Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects (2010) (125)
Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program. (2015) (124)
Effects of risperidone on auditory event-related potentials in schizophrenia. (1999) (119)
Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis (2006) (119)
Insight in first-episode psychosis (2006) (119)
Time-lapse mapping of cortical changes in schizophrenia with different treatments. (2009) (117)
Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia (2011) (115)
Metalloprotease-induced ectodomain shedding of neural cell adhesion molecule (NCAM). (2006) (115)
Placebo response in antipsychotic clinical trials: a meta-analysis. (2014) (114)
Schizophrenia: new pathological insights and therapies. (2007) (114)
Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. (2002) (112)
Qualitative assessment of brain morphology in acute and chronic schizophrenia. (1992) (112)
Abnormalities of the septum pellucidum on MR scans in first-episode schizophrenic patients. (1992) (112)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation (2015) (109)
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. (2010) (109)
The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia (2013) (108)
Maximizing clozapine therapy: managing side effects. (1998) (107)
Olanzapine increases allopregnanolone in the rat cerebral cortex (2000) (107)
Reduced anterior cingulate gyrus volume correlates with executive dysfunction in men with first-episode schizophrenia (2000) (105)
Recent advances in the neurobiology of schizophrenia. (2003) (105)
Auditory P300 in high-risk, recent-onset and chronic schizophrenia (2005) (105)
The deficit state in first-episode schizophrenia. (1994) (105)
Increased prevalence of the cavum septum pellucidum in magnetic resonance scans and post-mortem brains of schizophrenic patients (1992) (104)
Striatal Volume Changes in the Rat Following Long-term Administration of Typical and Atypical Antipsychotic Drugs (2002) (104)
Striatal enlargement in rats chronically treated with neuroleptic (1998) (104)
Prediction of relapse in schizophrenia. (1987) (104)
Effects of Ketamine, MK-801, and Amphetamine on Regional Brain 2-Deoxyglucose Uptake in Freely Moving Mice (2000) (103)
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. (2010) (103)
From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone (2005) (102)
Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. (1999) (102)
The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia (2005) (101)
Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations (2005) (101)
Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates. (1993) (101)
The NIMH-CATIE Schizophrenia Study: what did we learn? (2011) (101)
Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway (2008) (101)
Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder: A Randomized, Double-Blind, Fixed-Dose Study (2008) (100)
Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization (1999) (100)
A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia (2010) (98)
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. (2007) (97)
Antipsychotic medication effects on neuropsychological functions. (1992) (97)
Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study (2009) (97)
Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. (2004) (97)
Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia (1999) (95)
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. (2005) (94)
Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia (1996) (93)
Understanding the Mechanism of Action of Atypical Antipsychotic Drugs (1993) (93)
The evaluation and treatment of first-episode psychosis. (1997) (92)
Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia. (2003) (92)
Complement genes contribute sex-biased vulnerability in diverse illnesses (2020) (92)
Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects (2002) (92)
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial (2009) (92)
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. (2007) (91)
Olanzapine versus haloperidol in the treatment of first episode psychosis (1998) (90)
Cerebellar volume asymmetries are related to handedness: A quantitative MRI study (1995) (90)
Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. (2004) (90)
Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample (2011) (89)
The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. (1989) (89)
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). (2006) (88)
Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia (2001) (87)
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. (2011) (87)
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder (2005) (87)
Lack of association between the T→C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia (2001) (87)
Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. (2006) (87)
Genome-wide association study of antipsychotic induced QTc interval prolongation (2010) (87)
NCAM1 and Neurocognition in Schizophrenia (2007) (86)
An unstable trinucleotide-repeat region on chromosome 13 implicated in spinocerebellar ataxia: a common expansion locus. (2000) (85)
Genomewide association for schizophrenia in the CATIE study: results of stage 1 (2009) (85)
Mechanisms of Working Memory Impairment in Schizophrenia (2016) (84)
HLA associations in clozapine-induced agranulocytosis. (1995) (84)
Molecular pathophysiology of metabolic effects of antipsychotic medications (2014) (84)
Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial (2005) (83)
Components and correlates of family burden in schizophrenia. (2006) (82)
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial (2009) (82)
Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder (2015) (82)
Methylphenidate challenge as a predictor of relapse in schizophrenia. (1984) (81)
Measuring outcome priorities and preferences in people with schizophrenia (2005) (81)
Clinical profile of clozapine: Adverse reactions and agranulocytosis (2005) (81)
Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. (2010) (79)
Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality. (2019) (79)
Cerebral volume asymmetries in schizophrenia and mood disorders: a quantitative magnetic resonance imaging study. (1999) (79)
15. Follow up MRI study in first episode schizophrenia (1991) (79)
Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction (2006) (78)
Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. (2007) (78)
Myocarditis during clozapine treatment. (2006) (77)
Antipsychotic Drugs for First-Episode Schizophrenia (2009) (77)
Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. (2005) (76)
Neuroprotection in schizophrenia. (2006) (76)
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. (2004) (76)
Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first‐episode schizophrenia (2015) (76)
Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia. (1994) (76)
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1 (2008) (76)
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial (2018) (74)
Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: Candidate mechanism for superior efficacy? (2006) (74)
Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: Implications for therapeutic actions (2006) (74)
Diabetes and development of tardive dyskinesia. (1993) (72)
The Development of Treatment Resistance in Patients With Schizophrenia: A Clinical and Pathophysiologic Perspective (1998) (72)
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. (2006) (71)
Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers (1997) (71)
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. (2006) (71)
Perinatal Neurosteroid Levels Influence GABAergic Interneuron Localization in Adult Rat Prefrontal Cortex (2003) (71)
Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage. (2008) (70)
Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant (2010) (70)
Rechallenge in clozapine-induced agranulocytosis (1992) (70)
Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. (1997) (70)
Enduring effects of prenatal cocaine administration on emotional behavior in rats (2000) (69)
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response (2008) (69)
Presynaptic regulation of dopamine transmission in schizophrenia. (2011) (68)
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia (2017) (68)
Concurrent measurement of "real-world" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology. (2010) (67)
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. (2007) (67)
The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain (2012) (67)
Dexamethasone suppression tests in patients with panic disorder. (1983) (66)
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. (2002) (66)
Systematic analysis of dopamine receptor genes (DRD1–DRD5) in antipsychotic-induced weight gain (2010) (66)
Methylphenidate Response, Psychopathology and Tardive Dyskinesia as Predictors of Relapse in Schizophrenia (1994) (66)
The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. (1995) (66)
Genetic variation of 5-HT2A receptor and response to clozapine (1995) (66)
The present moment in psychotherapy and everyday life (2004) (65)
Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia (2006) (65)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia (2006) (65)
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. (2021) (65)
Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics (1996) (64)
Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia (1995) (64)
Predictors of response to clozapine. (1994) (64)
Prevalence of tardive dyskinesia in elderly samples. (1984) (63)
Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. (2010) (63)
Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. (1994) (62)
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis (2011) (62)
Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia (2000) (62)
Tricyclic antidepressant and metabolite levels in chronic renal failure (1985) (62)
Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia (2005) (61)
Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. (1994) (61)
Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state. (2009) (61)
A case report of cimetidine-induced clozapine toxicity. (1991) (60)
Psychotic Disorders. (2018) (60)
Association study of dopamine D3 receptor gene and schizophrenia. (1995) (60)
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study (2008) (60)
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial (2016) (59)
Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia (2013) (59)
Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. (2013) (58)
Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations (2006) (58)
New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. (2015) (58)
Cerebral morphometry and clozapine treatment in schizophrenia. (1994) (58)
A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial (2009) (57)
Duration of untreated psychosis and time to treatment response for delusions and hallucinations. (2005) (57)
Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials (2004) (56)
Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene (2012) (56)
A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy (2015) (56)
Neurobiology and the natural history of schizophrenia. (2006) (56)
11. Neuropsychological deficits in the early course of first episode schizophrenia (1991) (56)
Clinical implications of clozapine discontinuation: report of an NIMH workshop. (1995) (56)
Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes (2010) (55)
Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function (2002) (55)
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. (2011) (54)
22q11 DS: genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome (2002) (54)
Schizophrenia (maintenance treatment). (2009) (53)
Neuroprotection: A New Strategy in the Treatment of Schizophrenia (2007) (53)
Clozapine as a first treatment for schizophrenia. (2003) (53)
Renaming schizophrenia (2007) (52)
Treatment outcome of first episode schizophrenia. (1989) (52)
Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients (2013) (51)
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. (2019) (51)
Quantitative characterization of eye tracking dysfunction in schizophrenia (2000) (51)
Early detection and intervention in schizophrenia: a new therapeutic model. (2013) (51)
Perinatal allopregnanolone influences prefrontal cortex structure, connectivity and behavior in adult rats (2006) (50)
Cross-tapering clozapine and risperidone. (1995) (50)
Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia (2009) (50)
Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. (2009) (50)
Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls (1993) (50)
Family and case–control association study of the tumor necrosis factor-alpha (TNF-α) gene with schizophrenia and response to antipsychotic medication (2006) (50)
Hippocampal Shape and Volume Changes with Antipsychotics in Early Stage Psychotic Illness (2012) (49)
Introduction-Neuroprotection: A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia (2007) (49)
The American Psychiatric Publishing textbook of schizophrenia (2006) (49)
Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. (1992) (49)
A selective review of biological markers in schizophrenia. (1991) (49)
Prediction of outcome in first-episode schizophrenia. (1993) (49)
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care (2017) (49)
Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort (2017) (49)
Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response (2007) (48)
Adverse effects of psychotropic drugs (1992) (48)
Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors (2001) (48)
Polypharmacy in fatal clozapine-associated agranulocytosis (1991) (48)
Redefining the role of psychiatry in medicine. (1996) (48)
Agranulocytosis: incidence and risk factors. (1994) (47)
Clozapine-Induced Agranulocytosis (1995) (46)
Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. (2008) (46)
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia (2020) (46)
The usefulness and use of second-generation antipsychotic medications: Review of evidence and recommendations by a Task Force of the World Psychiatric Association. (2002) (45)
Absence of the Adhesio Interthalamica as a Marker of Early Developmental Neuropathology in Schizophrenia: An MRI and Postmortem Histologic Study (1998) (45)
HTR2C haplotypes and antipsychotics‐induced weight gain: X‐linked multimarker analysis (2007) (45)
Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia (2008) (45)
A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia (2016) (45)
Ethics in psychiatric research : a resource manual for human subjects protection (1999) (45)
Cognitive impairment in tardive dyskinesia (1985) (44)
Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis (2016) (44)
Tardive dyskinesia induced by risperidone? (1996) (44)
Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. (2010) (44)
Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases (1999) (43)
Lack of normal association between cerebellar volume and neuropsychological functions in first-episode schizophrenia. (2003) (43)
Methylphenidate and neuroleptic effects on oral word production in schizophrenia (1992) (42)
Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder. (2006) (42)
Incidence and correlates of tardive dyskinesia in first episode schizophrenia (1995) (42)
Reversed cerebellar asymmetry in men with First-Episode schizophrenia (2003) (42)
Intrinsic Regression Models for Manifold-Valued Data. (2009) (42)
The impact of obesity on health care costs among persons with schizophrenia. (2009) (41)
Caspase-3 Activation in Rat Frontal Cortex Following Treatment with Typical and Atypical Antipsychotics (2007) (41)
Brain morphometric comparison of first-episode schizophrenia and temporal lobe epilepsy (1997) (41)
Family attributions and coping in the prediction of emotional adjustment in family members of patients with first‐episode schizophrenia (1999) (40)
Clozapine effects on tardive dyskinesia. (1989) (40)
COMT158 polymorphism and hostility (2004) (40)
Olanzapine for Schizophrenia Refractory to Typical and Atypical Antipsychotics: An Open-Label, Prospective Trial (2001) (39)
Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. (2006) (39)
Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia. (2007) (39)
Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function (2009) (39)
Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression (2010) (39)
Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects (2005) (38)
Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. (2010) (36)
Neurocognition in early-onset schizophrenia and schizoaffective disorders. (2010) (36)
Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. (1989) (36)
Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample (2015) (36)
No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis. (1996) (36)
Macroscopic fast neuronal oscillations and synchrony in schizophrenia. (2004) (36)
Clozapine response in treatment-refractory first-episode schizophrenia (1994) (36)
A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. (1994) (36)
Association of RGS2 and RGS5 variants with schizophrenia symptom severity (2008) (36)
Clozapine, negative symptoms, and extrapyramidal side effects. (1994) (35)
Single‐voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulate and hippocampus (2006) (34)
Dexamethasone suppression tests in patients with obsessive-compulsive disorder. (1985) (34)
Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic‐induced weight gain in European and African‐American schizophrenia patients (2010) (34)
Pharmacologic characterization of tardive dyskinesia. (1988) (34)
Psychoneuroendocrinology of schizophrenia. (1998) (34)
Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate. (1982) (34)
Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients (2009) (34)
Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration (2012) (33)
Schizophrenia and substance abuse. (1993) (33)
The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. (2012) (33)
Comprehensive care of schizophrenia : a textbook of clinical management (2001) (33)
A predictive model for conversion to psychosis in clinical high-risk patients (2018) (33)
Chronic Administration of Haloperidol and Olanzapine Attenuates Ketamine-Induced Brain Metabolic Activation (2003) (33)
The role of genetic variation across IL-1β, IL-2, IL-6, and BDNF in antipsychotic-induced weight gain (2015) (33)
Management of clozapine-induced enuresis. (1995) (32)
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. (2011) (32)
Neuropsychological deficits in the early course of first episode schizophrenia. (1991) (32)
A systematic method for estimating individual responses to treatment with antipsychotics in CATIE (2009) (32)
Methylphenidate decreases regional cerebral blood flow in normal human subjects. (1994) (32)
Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study (2011) (32)
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition (2008) (32)
Epidemiology of Tardive Dyskinesia (1983) (32)
The Behavioral Toxicity of Bromocriptine in Patients with Psychiatric Illness (1989) (31)
IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness (2000) (31)
Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. (2016) (31)
Premature disinhibition of P3 generation in schizophrenia (1996) (31)
Population Pharmacokinetics of Perphenazine in Schizophrenia Patients From CATIE: Impact of Race and Smoking (2010) (31)
Caveat Emptor: Researcher Beware (1999) (31)
Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats (2004) (30)
Developmental Effects of Prenatal Cocaine Exposure on 5-HT1A Receptors in Male and Female Rat Offspring (2003) (30)
Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. (2012) (30)
Analysis of genome-wide CAG/CTG repeats, and at SEF2-1B and ERDA1 in schizophrenia and bipolar affective disorder (1999) (30)
The catechol-O-methyl-transferase gene in tardive dyskinesia (2010) (29)
Follow-up MRI study in first episode schizophrenia Gustav Degreef, M.D., Manzar Ashtari, Ph.D., Howard Wu, B. Med., Michael Borenstein, Ph.D., Jeffrey Lieberman, M.D. Albert Einstein College of Medicine, Hillside Hospital, P.O. Box 38, Glen Oaks, NY 11004 (1991) (29)
On the Possible Mechanisms and Predictability of Clozapine-Induced Agranulocytosis (1992) (29)
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode (2005) (29)
Schizophrenia: new phenes and new genes. (1999) (29)
Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia. (1990) (29)
Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine (2018) (29)
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. (2012) (29)
Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. (2014) (28)
Obstetric complications predict treatment response in first-episode schizophrenia (1999) (28)
Characterization of in vivo Pharmacokinetic Properties of the Dopamine D1 Receptor Agonist DAR-0100A in Nonhuman Primates Using PET with [11C] NNC112 and [11C] Raclopride (2011) (28)
Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses (2012) (28)
Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia (2008) (28)
A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia (2014) (28)
Shrinks: The Untold Story of Psychiatry (2015) (27)
Ethical principles and practices for research involving human participants with mental illness. (2006) (27)
Amphetamine-Induced Fos is Reduced in Limbic Cortical Regions but not in the Caudate or Accumbens in a Genetic Model of NMDA Receptor Hypofunction (2004) (27)
Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. (1998) (27)
Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients (2020) (27)
Secretin for refractory schizophrenia (2004) (26)
Evidence for a biological hypothesis of obsessive-compulsive disorder. (1984) (26)
Obstetric complications in schizophrenia, schizoaffective disorder and normal comparison subjects (1999) (26)
Reconsidering the Classification of Schizophrenia and Manic Depressive Illness — A Critical Analysis and Mew Conceptual Model (2003) (26)
Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity (2006) (26)
Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia (2011) (26)
Antipsychotics: Past and Future: National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998. (1999) (26)
Pharmacologic studies of tardive dyskinesia. (1988) (26)
Neurodevelopmental and neurodegenerative hypotheses of schizophrenia: a review and critique (2003) (26)
The Behavioral Effect of m-Chlorophenylpiperazine (mCPP) and Methylphenidate in First-Episode Schizophrenia and Normal Controls (1995) (26)
Clinical phenomenology. (1988) (26)
Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia (2008) (26)
Brain volumes in psychotic youth with schizophrenia and mood disorders. (2010) (25)
Developing novel antipsychotic drugs: Strategies and goals (2000) (25)
Brain morphometric comparison of first episode schizophrenia and temporal lobe epilepsy (1993) (25)
Neuromuscular effects of monoamine oxidase inhibitors. (1985) (25)
The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response (2011) (25)
Comprehensive Care of Schizophrenia (2001) (25)
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type (2013) (25)
Drugs of the psychopharmacological revolution in clinical psychiatry. (2000) (24)
Advancing drug discovery for schizophrenia (2011) (24)
HLA associations in clozapine-induced agranulocytosis (1995) (24)
Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study) (2011) (23)
Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia (2003) (23)
Intrinsic Regression Models for Manifold-Valued Data (2009) (23)
A multicenter study of ketamine effects on functional connectivity: Large scale network relationships, hubs and symptom mechanisms (2019) (23)
Akathisia and clozapine treatment. (1993) (23)
Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder (2021) (23)
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. (2012) (22)
Fat Mass- and Obesity-Associated (FTO) Gene and Antipsychotic-Induced Weight Gain: An Association Study (2014) (22)
The dopamine-serotonin relationship in clozapine response (1993) (22)
Association of orexin receptor polymorphisms with antipsychotic-induced weight gain (2016) (22)
Longitudinal perspectives on the pathophysiology of schizophrenia Examining the neurodevelopmental versus neurodegenerative hypotheses (1991) (22)
Successful rechallenge with clozapine after eosinophilia. (2011) (22)
Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia (2019) (22)
Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features (2004) (22)
Caudate Shape Discrimination in Schizophrenia Using Template-Free Non-parametric Tests (2003) (22)
Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients (2010) (22)
Myoclonus during treatment with clozapine and lithium: the role of serotonin. (1989) (22)
MRI changes during water loading in patients with polydipsia and intermittent hyponatremia. (1999) (22)
Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study (2011) (22)
Clozapine pharmacology and tardive dyskinesia (2004) (21)
The use of clozapine in neurologic disorders. (1994) (21)
Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. (2011) (21)
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers (2020) (21)
Second-generation antipsychotics: reviewing the cost–effectiveness component of the CATIE trial (2007) (21)
A Longitudinal Study of Violent Behavior in a Psychosis-Risk Cohort (2018) (21)
Antipsychotic binding to the dopamine-3 receptor in humans: A PET study with [11C]-(+)-PHNO (2015) (21)
Erratum: Genomewide association for schizophrenia in the CATIE study: Results of stage 1 (Molecular Psychiatry (2008) 13 (570-584) DOI: 10.1038/mp.2008.25) (2009) (21)
Improving classification of psychoses. (2016) (21)
RanBP1, a velocardiofacial/DiGeorge syndrome candidate gene, is expressed at sites of mesenchymal/epithelial induction (2002) (20)
HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. (1994) (20)
Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia (2005) (20)
A PstI restriction fragment length polymorphism in the 5′ untranslated region of DRD4 is not associated with schizophrenia (1996) (20)
Aripiprazole versus haloperidol treatment in early-stage schizophrenia. (2011) (20)
Anatomical Abnormalities in Gray and White Matter of the Cortical Surface in Persons with Schizophrenia (2013) (20)
CSF 5-hydroxyindoleacetic acid levels and suicide attempts in schizophrenia (1990) (20)
Substance abuse comorbidity in schizophrenia: editors' introduction. (1990) (20)
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. (2009) (20)
Distinct Relationships Between Visual and Auditory Perceptual Abnormalities and Conversion to Psychosis in a Clinical High-Risk Population (2017) (20)
Do white-cell count spikes predict agranulocytosis in clozapine recipients? (1995) (19)
No association of the serotonin transporter polymorphisms 5‐HTTLPR and RS25531 with schizophrenia or neurocognition (2010) (19)
The Rapid Rise in Investment in Psychedelics-Cart Before the Horse. (2022) (19)
Neuropsychological studies of first episode schizophrenia (1991) (19)
Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: a pilot study. (1995) (19)
Psychiatry: Tasman/Psychiatry (2008) (19)
Towards diagnostic markers for the psychoses. (2016) (19)
Exploratory study on association of genetic variation in TBC1D1 with antipsychotic‐induced weight gain (2013) (19)
Variability in Response to Clozapine: Potential Role of Cytochrome P450 1A2 and the Dopamine D4 Receptor Gene (1999) (19)
Association Study of GABAA &agr;2 Receptor Subunit Gene Variants in Antipsychotic-Associated Weight Gain (2015) (19)
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo (2018) (18)
Tardive dyskinesias and drugs (1986) (18)
Deep resequencing and association analysis of schizophrenia candidate genes (2013) (18)
Correlates of substance misuse in patients with first‐episode schizophrenia and schizoaffective disorder (2001) (18)
Prediction of relapse in schizophrenia. (1986) (18)
Neurodegenerative model of schizophrenia: Growing evidence to support a revisit (2022) (18)
Methylphenidate challenge tests and course of schizophrenia. (1985) (17)
Association Between the Duration of Untreated Psychosis and Selective Cognitive Performance in Community-Dwelling Individuals With Chronic Untreated Schizophrenia in Rural China. (2020) (17)
Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects (2009) (17)
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. (2005) (17)
756 The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics (1997) (17)
Neuroleptic-Induced Movement Disorders: Aging and tardive dyskinesia (1996) (17)
Genetic association analysis of N‐methyl‐d‐aspartate receptor subunit gene GRIN2B and clinical response to clozapine (2016) (17)
Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response (2010) (17)
Handbook of Psychiatric Drugs (2006) (16)
Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia. (2002) (16)
Normal eye tracking is associated with abnormal morphology of medial temporal lobe structures in schizophrenia (1992) (16)
The Power of Hope: A Doctor's Perspective (1999) (16)
Neuroleptic treatment of elderly patients. (1995) (16)
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404)) (2009) (16)
The Effect of Activation Procedures on Neuroleptic-Induced Akathisia (1993) (16)
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? (2013) (16)
Neuropathological and Brain Imaging Studies in Positive and Negative Schizophrenia (1991) (16)
Association study of GRIK1 gene polymorphisms in schizophrenia: case–control and family‐based studies (2012) (15)
Conflict of interest-- an issue for every psychiatrist. (2009) (15)
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. (2014) (15)
A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects. (1995) (15)
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building (2012) (15)
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder (2001) (15)
Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia (2007) (15)
Getting the Facts Straight About Gun Violence and Mental Illness: Putting Compassion Before Fear (2013) (15)
Increased prevalence of the cavum septum pellucidum in MRI scans and postmortem brains of schizophrenic patients (1992) (15)
Time to treatment response in successive episodes of early onset schizophrenia (1995) (15)
Meeting the Mental Health Challenge of the COVID-19 Pandemic (2020) (14)
The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia (2013) (14)
ANTIBODIES TO ACETYLCHOLINE RECEPTORS IN TARDIVE DYSKINESIA (1984) (14)
Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study (2011) (14)
Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain (2018) (14)
Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians (2010) (14)
A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. (2016) (14)
High-impact rare genetic variants in severe schizophrenia. (2021) (14)
Rib fractures as an unusual complication of severe tardive dystonia. (1993) (14)
Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial (2010) (14)
Anticholinergic delirium caused by retreatment with clozapine. (1991) (14)
AKT1 and Neurocognition in Schizophrenia (2007) (14)
Ziprasidone alternative for olanzapine-induced hyperglycemia. (2002) (14)
Hormonal response to fenfluramine challenges in clozapine-treated schizophrenic patients (1991) (14)
Schizophrenia (maintenance treatment). (2010) (13)
Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. (2015) (13)
Comparing safety and tolerability of antipsychotic treatment. (2007) (13)
The efficacy of amoxapine, maprotiline, and trazodone in comparison to imipramine and amitriptyline: a review of the literature. (1984) (13)
Age and treatment related local hippocampal changes in schizophrenia explained by a novel shape analysis method (2003) (13)
Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. (1994) (13)
Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia (1995) (13)
Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis (2018) (13)
Seasonal Admission Patterns in First Episode Psychosis, Chronic Schizophrenia, and Nonschizophrenic Psychoses (2001) (13)
Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine (2016) (13)
High plasma clozapine levels in tardive dyskinesia. (1993) (13)
Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia (2010) (13)
Atypical Antipsychotic Drugs in Treatment-Refractory Schizophrenia (1998) (13)
Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia (2003) (13)
Clozapine and akathisia (1992) (13)
Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness (2018) (12)
Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. (1998) (12)
Association study of the gamma-aminobutyric acid type a receptor γ2 subunit gene with schizophrenia (2009) (12)
Gonadal hormones, sex and behavior. (1990) (12)
Pharmacotherapy for Patients with First-Episode, Acute, and Refractory Schizophrenia (1996) (12)
No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain (2014) (12)
Clinical and Pharmacological Studies in Psychiatric Disorders (1987) (12)
Ventricular system morphology in first episode schizophrenia: A volumetric study of ventricular subdivisions on MRI (1990) (12)
Neurons and Networks: An Introduction to Neuroscience (1995) (12)
Signs and symptoms. What can they tell us about the clinical course and pathophysiologic processes of schizophrenia? (1995) (12)
What the CATIE study means for clinical practice. (2006) (12)
Ethical dilemmas in clinical research with human subjects: an investigator's perspective. (1996) (11)
Epidemiological aspects of tardive dyskinesia. (1988) (11)
Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: Preliminary findings (1995) (11)
Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia (2005) (11)
Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Treatment Strategies in Schizophrenia Collaborative Study Group. (1989) (11)
Facial emotion perception and fusiform gyrus volume in first episode schizophrenia (2005) (11)
Young Brains on Drugs (2014) (11)
Evidence for sensitization in the early stage of schizophrenia (1992) (11)
Use of Antipsychotics Pre- and Post-Dissemination of CATIE Data. (2007) (11)
The prevalence of tardive dyskinesia. (1985) (11)
Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. (2005) (11)
Guest editors' introduction: what can large pragmatic clinical trials do for public mental health care? (2003) (11)
Yakovlevian torque is absent in first episode schizophrenia (1993) (11)
Akathisia and clozapine treatment (1993) (11)
Adjusted Exponentially Tilted Likelihood with Applications to Brain Morphology (2009) (11)
Psychiatry: Behavioral Science and Clinical Essentials (1999) (11)
Polydipsia and tardive dyskinesia in chronic psychiatric patients--related disorders? (1993) (11)
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans (2019) (10)
Alive but not well: the limited validity but continued utility of the concept of schizophrenia (2017) (10)
Mood responses of remitted schizophrenics to methylphenidate infusion (2005) (10)
Predictors of relapse in schizophrenia (1986) (10)
Growth hormone response to growth hormone-releasing hormone in schizophrenic patients. (1990) (10)
Erratum: The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeuthic approaches (Biological Psychiatry 50:11 (884-897)) (2002) (10)
First-episode psychosis in a managed care setting: clinical management and research. (2000) (10)
Erratum: Striatal Volume Changes in the Rat Following Long-term Administration of Typical and Atypical Antipsychotic Drugs* (2002) (10)
Protein kinase cAMP‐dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic‐induced weight gain (2014) (10)
Neural correlates of automatic and controlled auditory processing in schizophrenia. (2008) (10)
Gadolinium-DTPA enhanced gradient echo magnetic resonance scans in first episode of psychosis and chronic schizophrenic patients (1991) (10)
Psychotic symptoms in mass shootings v. mass murders not involving firearms: findings from the Columbia mass murder database (2021) (10)
Dr. Robinson and Colleagues Reply (1995) (10)
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial (2009) (10)
Practical applications of recent antipsychotic effectiveness data. (2007) (10)
No evidence for parental imprinting of mouse 22q11 gene orthologs (2006) (9)
Interpreting the results of the CATIE study. (2006) (9)
Effects of the D 1 Dopamine Receptor Agonist Dihydrexidine ( DAR-0100 A ) on Working Memory in Schizotypal Personality Disorder (2014) (9)
Syncope associated with the combination of clozapine and enalapril. (1994) (9)
Handbook of Psychiatric Drugs: Lieberman/Handbook of Psychiatric Drugs (2006) (9)
It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists (2008) (9)
Clinical applications of neuroimaging in psychiatry. (1998) (9)
What the BRAIN Initiative means for psychiatry. (2014) (9)
Consistency of treatment response across successive psychotic episodes in recent-onset schizophrenia (1993) (9)
Synaptophysin and PSD-95 in the human prefrontal cortex from mid-gestation into early adulthood (2007) (9)
Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia (2019) (9)
Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH schizophrenia trials network study (2007) (8)
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation (2005) (8)
Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia (2010) (8)
Predictors of treatment response and course of schizophrenia (1993) (8)
Measurement of lithium concentrations in human tears. (1982) (8)
544 Olanzapine versus haloperidol in the treatment of first episode psychosis (1997) (8)
P.3.d.033 Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial (2013) (8)
MDR1 gene in tardive dyskinesia scale scores: Comparison of strategies for quantitative trait haplotype analysis (2009) (8)
Attentional modulation of early-stage visual processing in schizophrenia (2006) (8)
Association of 9-Hydroxy Risperidone Concentrations With Risk of Switching or Discontinuation in the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial (2010) (8)
First-episode Psychosis: Part I. Editors' Introduction (1992) (8)
Perinatal flunitrazepam exposure causes persistent alteration of parvalbumin-immunoreactive interneuron localization in rat prefrontal cortex (2004) (7)
Investigation of melanocortin system gene variants in antipsychotic-induced weight gain (2014) (7)
Teaching trainees to negotiate research collaborations with industry: a mentorship model. (2010) (7)
Advances in the Management of Treatment- Resistant Schizophrenia (2010) (7)
Psychiatrists Diagnosing the President - Moral Imperative or Ethical Violation? (2018) (7)
Clinical correlates of weight gain in first episode psychosis patients treated with olanzapine (2003) (7)
Spastic dysphonia and denervation signs in a young man with tardive dyskinesia (1989) (7)
P.3.d.057 Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a double-blind, placebo-controlled trial (2015) (7)
An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS (2020) (7)
Eliminating the Glass Ceiling in Academic Psychiatry (2017) (7)
Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis (2020) (7)
Lack of association between HTR4 gene polymorphisms and schizophrenia in case–control and family-based samples (2010) (7)
New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach (2019) (7)
Brain morphology in first episode schizophrenia (1991) (7)
Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics. (2006) (7)
The impossible dream: can psychiatry prevent psychosis? (2007) (7)
Schizophrenia, VI: Treatments. (2003) (6)
Structural neuroimaging of psychiatry disease: Reliable and efficient automatic brain tissue segmentation for increased sensitivity (2001) (6)
0394 CLINICAL EFFECTIVENESS AND PREDICTORS OF TREATMENT NON-ADHERENCE: COMPARISON OF OLANZAPINE, QUETIAPINE, AND RISPERIDONE IN FIRST-EPISODE PSYCHOSIS (2006) (6)
Brain Regions Associated With Internalizing and Externalizing Psychiatric Symptoms in Patients With Penetrating Traumatic Brain Injury. (2016) (6)
A Selective Review of Recent Advances in the Management of Tardive Dyskinesia (1993) (6)
Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective (2011) (6)
Lack of association of NALCN genetic variants with schizophrenia (2011) (6)
Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study (2020) (6)
A VOLUMETRIC MRI STUDY OF LIMBIC STRUCTURES IN CHRONIC SCHIZOPHRENIA ‐ RELATIONSHIP TO PSYCHOPATHOLOGY (1992) (6)
Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective (2018) (6)
TWO-STAGE EMPIRICAL LIKELIHOOD FOR LONGITUDINAL NEUROIMAGING DATA. (2011) (6)
Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia (2018) (6)
New-Onset Tardive Dyskinesia in Patients With First-Episode Psychosis Receiving Risperidone or Haloperidol (2006) (6)
Association study between the neurexin‐1 gene and tardive dyskinesia (2017) (6)
553 Pilot study of atypical antipsychotic agents in first episode schizophrenia (1997) (6)
Psychosis and genes with trinucleotide repeat polymorphism (1996) (6)
Anti-viral properties of antipsychotic medications in the time of COVID-19 (2020) (6)
Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia † (2020) (6)
Clinical Research in the Age of Neuroscience (2000) (6)
Essentials of Schizophrenia (2011) (6)
Olanzapine induced reductions in frontal lobe lactate levels correlate with treatment response in first episode psychosis (2003) (6)
Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain (2017) (6)
Dr. Lieberman and Colleagues Reply (2006) (5)
From known to unknown; old to new: can lesion studies inform psychiatry about mental illness in the 21st century? (2012) (5)
Mismatch negativity (MMN) in first episodic and chronic schizophrenic subjects (1995) (5)
Chapter 3.5 – Atypical antipsychotic drugs and stress (2005) (5)
Biologic indices of heterogeneity in schizophrenia: Relationship to psychopathology and treatment outcome (1991) (5)
Pocket companion to accompany psychiatry (1998) (5)
Unrelated agranulocytosis in a patient taking clozapine. (1993) (5)
Antipsychotic Trials in Schizophrenia: Study design and protocol development process (2010) (5)
Course and predictors of weight gain in people Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine with first-episode psychosis treated with olanzapine (2005) (5)
Back to the future: Research renewed on the clinical utility of psychedelic drugs (2016) (5)
Back to the Future - The Therapeutic Potential of Psychedelic Drugs. (2021) (5)
Psychiatry: Nothing to Be Defensive About (2013) (5)
Behavioral responses to a dopaminergic challenge in obsessive-compulsive disorder (1991) (5)
P.3.c.054 Olanzapine, quetiapine, and risperidone in the treatment of first-episode psychosis: effectiveness and factors influencing adherence to treatment (2006) (5)
Predictors of outcome in schizophrenia: the concept of time (1994) (5)
Clozapine and tardive dyskinesia: Prospective data (1991) (5)
Schizophrenia‐associated gene dysbindin‐1 and tardive dyskinesia (2020) (5)
The moral imperatives of medical research in human subjects. (1994) (4)
Antipsychotic Trials in Schizophrenia: List of contributors (2010) (4)
Clinical Efficacy and Target Engagement of Glutamatergic Drugs: Placebo-Controlled RCTs of Pomaglumetad and TS-134 for Reversal of Ketamine-Induced Psychotic Symptoms and PharmacoBOLD in Healthy Volunteers (2020) (4)
Are Placebo-Controlled, Relapse Prevention Trials in Schizophrenia Research Still Necessary or Ethical? (2019) (4)
Correlates of course and outcome in first-episode schizophrenia (1991) (4)
PHOSPHODIESTERASE 4B GENETIC VARIANTS ARE NOT ASSOCIATED WITH ANTIPSYCHOTIC-INDUCED TARDIVE DYSKINESIA (2010) (4)
Decline of dopamine: effects of age and acute neuroleptic challenge. (1998) (4)
Sedative–Hypnotic Agents (2006) (4)
Improvement in markers of health status 6 weeks after switching from olanzapine to ziprasidone (1999) (4)
Intrinsic Regression Models for Medial Representation of Subcortical Structures (2012) (4)
Searching for the neuropathology of schizophrenia: neuroimaging strategies and findings. (1999) (4)
Starting a Career in Psychiatric Research (2001) (4)
Introduction. Quetiapine: A 5-Year Update (2002) (4)
Neurodevelopment and Schizophrenia: Neurodegenerative models of schizophrenia (2004) (3)
Neuroimaging, neurodevelopment, and schizophrenia (1997) (3)
Common Variants near the Melanocortin 4 Receptor Gene are Associated with Severe Antipsychotic Drug-induced Weight Gain (2014) (3)
Clozapine And Weight Gain - Association With Clinical Response And Long-Term Course (1994) (3)
The deficit state in a prospective study of first-episode schizophrenia (1992) (3)
The Dangerous Case of Psychiatrists Writing About the POTUS’s Mental Health (2017) (3)
Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology (2020) (3)
Deep Learning Substitutes Gadolinium in Detecting Functional and Structural Brain Lesions with MRI (2020) (3)
Psychiatry Embraces Patient-Centered Care (2014) (3)
Prospective MRI study of caudate pathomorphology in first episode schizophrenia (1993) (3)
A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise (2020) (3)
Prevalence of tardive dyskinesia in elderly samples. (1984) (3)
CT morphology and short term outcome in schizophrenia (1989) (3)
Independence of morphologic markers in schizophrenia (1994) (3)
Age of onset in schizophrenia (1995) (3)
Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis (2003) (3)
A single estimate of separate within-individual correlations: applications in psychopharmacology. (1990) (2)
A study using gadopenetetate dimeglumine enhanced MRI scans in schizophrenia (1989) (2)
Tricyclic Antidepressant Drug and Metabolite Levels in Chronic Renal Failure (1986) (2)
Plasma homovanillic acid in first-episode schizophrenia: Psychopathology and treatment response (1993) (2)
The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures (2019) (2)
An interview with Jeffrey A. Lieberman: Tardive Dyskinesia. [interview by Sussman Norman]. (2007) (2)
Dopamine Pathophysiology in Tardive Dyskinesia (1989) (2)
Recency and intensification of positive symptoms enhance prediction of conversion to syndromal psychosis in clinical high-risk patients (2019) (2)
Neopterin and biopterin CSF levels in tardive dyskinesia after clozapine treatment (1993) (2)
The Ketamine Challenge: When Practice Leaps Ahead of Science (2015) (2)
Tardive dyskinesia induced by risperidone? [9] (1996) (2)
P.3.e.017 Effects of alpha7 nicotinic receptor agonist TC-5619 in cognitive dysfunction in schizophrenia (2011) (2)
ReviewCatching Up on Schizophrenia : Natural (2000) (2)
S shape analysis of neuroanatomical structures based on medial models (2003) (2)
Improving Mental Health Care in America: An Opportunity for Comprehensive Reform (2017) (2)
Revised PORT recommendations. (2004) (2)
Drug attitudes and treatment adherence in a clinical trial comparing haloperidol and olanzapine in first episode schizophrenia (2003) (2)
Novel histamine H1 gene polymorphism and clozapine-induced weight gain (2000) (2)
74. Incidence of suicide in a research study of first episode schizophrenia (1996) (2)
Deficits in mismatch negativity in schizophrenia: Predictor of outcome or result of illness progression? (2003) (2)
Shrinks: The Untold Story of Psychiatry, by Jeffrey A. Lieberman, M.D., with Ogi Ogas: A Critical Discussion (2015) (2)
Hippocampal Glutamate and Positive Symptom Severity in Clinical High Risk for Psychosis. (2021) (2)
Temporal limbic structure volumes and psychopathology in chronic schizophrenia (1992) (2)
Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study (2020) (2)
Gender differences in the presentation, course, and outcome of first episode schizophrenics (1992) (2)
Liver enzyme CYP2D6 gene and tardive dyskinesia. (2020) (2)
Recent Advances in the Clinical Use of Atypical Antipsychotics (2005) (2)
S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia (2003) (2)
Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine (2018) (2)
Memory deficits in first episode schizophrenia: Beyond impaired acquisition (1995) (1)
Erratum: The evaluation and treatment of first-episode psychosis (Schizophrenia Bulletin (1997) 23 (653-661)) (2006) (1)
Schizophrenia Spectrum and Other Psychotic Disorders (2019) (1)
Neonatal neurosteroid administration alters adult parvalbumin immunoreactivity in rat prefrontal cortex and thalamus (2003) (1)
452 Obstetric complications and brain MRI findings in schizophrenia (1997) (1)
Bipolar disorder: A syndrome in evolution (2004) (1)
DISPUTING PSYCHIATRY'S REDEFINITION. AUTHORS' REPLY (1997) (1)
S-43-4 Evidence for sensitization in the early stage of schizophrenia (1996) (1)
579 Obstetric complications predict treatment response in first episode schizophrenia (1997) (1)
Mass murders involving firearms and other methods in school, college, and university settings: Findings from the Columbia Mass Murder Database (2022) (1)
Drs. Umbricht and Lieberman Reply (1994) (1)
Clozapine Response In Chronic Schizophrenia And Brain Morphology On MRI: A Preliminary Report (1994) (1)
Neuropsychological responses to stimulant challenge in schizophrenia (1989) (1)
The neurobiology of duration of untreated psychosis: a comprehensive review (2022) (1)
New insights into classical issues in schizophrenia (1994) (1)
Antipsychotic Trials in Schizophrenia: Violence in schizophrenia: prevalence, correlates, and treatment effectiveness (2010) (1)
How should we diagnose schizophrenia: Don't throw the baby out with the bath water (2022) (1)
Negative Symptoms and Cognitive Deficits (2020) (1)
P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia (2003) (1)
Schizophrenia: comments on genes, development, risk factors, phenotype, and course. (1999) (1)
Predictors of response to clozapine in chronic schizophrenia (1993) (1)
Caudate nucleus volume and cognitive deficit in first episode psychosis (1997) (1)
BORDERLINE PERSONALITY DISORDER : INTERFACE WITH MOOD AND OTHER AXIS I DISORDERS — (2004) (1)
Hypothesis and hypothesis testing in the clinical trial. (2001) (1)
Neuropsychological profiles of first episode schizophrenia (1995) (1)
Marijuana Legalization and Young Brains: Time for Serious Study (2014) (1)
Comparative effectiveness of antipsychotic drugs. Commentary (2006) (1)
713 Obstetric complications in schizophrenia, affective disorder and normal controls (1997) (1)
Change, Challenge and Opportunity: Psychiatry in Age of Reform and Enlightenment (2013) (1)
PATHOPHYSIOLOGY OF SCHIZOPHRENIA: Neurodevelopmental and Neurodegenerative Processes (2001) (1)
Milestones in the History of Schizophrenia. A Comprehensive Chronology of Schizophrenia Research: What Do We Know and When Did We Know It (2021) (1)
Memory impairment in first episode schizophrenia (1995) (1)
Training the Psychiatrist of the Future (2013) (1)
Growth hormone response to growth hormone releasing factor in schizophrenia (1989) (1)
An exploratory magnetic resonance imaging study of suicidal ideation in individuals at clinical high-risk for psychosis (2021) (1)
Drs. Lieberman, Javitch, and Moore Reply (2009) (1)
Teaching Trainees to N egotiate R esearch C ollaborations W ith Industry: A M entorship M odel (2010) (1)
Antibodies to Acetylcholine Receptors in Patients with Tardive Dyskinesia (1984) (1)
79-4 Evidence for sensitization in the early stage of schizophrenia (1997) (1)
Dr. Penn and Colleagues Reply (2006) (1)
POLYDIPSIA, TARDIVE DYSKINESIA, AND DOPAMINE SUPERSENSITIVITY. AUTHORS' REPLY (1994) (1)
Is bromocriptine a dopamine antagonist treatment? (1983) (1)
NMDAR and D1 receptor genes in the response to clozapine treatment and negative symptoms (2005) (1)
Olanzapine versus haloperidoi treatment in first-episode psychosis (1998) (1)
Investigation of olanzapine-associated weight gain in first episode subjects (2003) (1)
Diagnostic stability in patients followed from their first episode of schizophrenia or schizoaffective disorder (1995) (1)
Schizophrenia Study: What Did We Learn? (2012) (1)
Our future is now. (2014) (1)
Second International Symposium on the Economic and Social Costs of Substance Abuse (1997) (1)
227. Validation Study in Two Genome-Wide Significant Risk Variants for Antipsychotic-Induced Weight Gain (2017) (1)
Social adjustment and outcome in first episode schizophrenia (1993) (1)
Five year follow-up of outcome in a prospective study of first-episode schizophrenia at Hillside hospital (1995) (1)
Ethics of Drug Discontinuation Studies in Schizophrenia-Reply (1989) (1)
Poster #T48 INVESTIGATION OF THE PRO-MELANIN-CONCENTRATING HORMONE GENE IN ANTIPSYCHOTIC INDUCED WEIGHT GAIN (2014) (1)
Management of victims of torture (2008) (1)
DSM Crosses the Finish Line (2012) (1)
Robert Spitzer: A Psychiatrist for the Ages (2016) (1)
Correction: Anatomical Abnormalities in Gray and White Matter of the Cortical Surface in Persons with Schizophrenia (2013) (1)
Foreword (2005) (1)
Mesiotemporal volumes and asymmetry in first episode schizophrenics: A baseline and follow-up study (1996) (1)
The neurobiology of auditory and visual perceptual abnormalities in a clinical high-risk for psychosis cohort: A pilot morphometric magnetic resonance imaging study. (2021) (1)
Antipsychotic adverse reactions in schizophrenia: A pharmacogenetic study of weight gain and tardive dyskinesia. (2000) (1)
Comprar Essentials of Schizophrenia | T. Scott Stroup | 9781585624010 | American Psychiatric Publishing (2011) (1)
746 First episode schizophrenia and borna disease virus (1997) (1)
Response to the presidential address. (2013) (1)
Pharmacotherapy of Schizophrenia (2007) (1)
Solving the Mystery of Military Mental Health: A Call to Action (2018) (1)
This Excerpt Is from Chapter 104 Complementary and Alternative Treatments in Psychiatry (2009) (0)
TC18C MRI OF BRAIN VOLUMES AT THE PRODROME AND FIRST EPISODE STAGES OF SCHIZOPHRENIA (2006) (0)
Research report A in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function (2002) (0)
Prepubertal Psychosis: A Case Control Study (1994) (0)
Increased parietal and occipital lobe gyrification predicts conversion to syndromal psychosis in a clinical high-risk cohort (2023) (0)
233. Effects of dopaminergic modulation on trait-like redundancy in schizophrenia (1998) (0)
Electroconvulsive Therapy in Schizophrenia (2020) (0)
Herbert D. Kleber (2019) (0)
92-2 Co-morbidity issues in the treatment of schizophrenia (1997) (0)
20-3 The psychobiology of first episode schizophrenia (1997) (0)
Contents Vol. 2, 2016 (2017) (0)
262. Methylphenidate effects on verbal fluency in schizophrenia (1996) (0)
117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment (2019) (0)
P.3.a.047 Remission in schizophrenia: a comparison of 2 dose regimens of ziprasidone versus haloperidol in a 40-week core and 3-year double-blind continuation study (2006) (0)
T38 Preliminary Model For The Genetic Prediction Of Clozapine Response (2017) (0)
CT morphology and outcome in schizophrenia (1993) (0)
Alpha-1A adrenergic (ADRA1A) and serotonin 6 (HTR6) receptor gene polymorphisms and clinical response to clozapine (2001) (0)
68. Temporal lobe structure angulation in first-episode schizophrenia (1996) (0)
Influence of the risk for psychosis on facial affect recognition and threat evaluation in marijuana users (2013) (0)
104. Antipsychotic Drugs (2015) (0)
Comprar Solid State Polymerization | Allan Tasman | 9780470084182 | Wiley (2009) (0)
71. Atypical antipsychotic medication in the treatment of first episode schizophrenia (1996) (0)
F103NEW GENETIC FINDINGS IN TARDIVE DYSKINESIA: FROM CYP2D6 TO C4 (2019) (0)
Decreased PAR-4 in the temporal cortex of subjects with schizophrenia (2003) (0)
Psychiatric Ramications of the COVID-19 Pandemic (2020) (0)
Plasma levels of Fluphenazine and prolactin in maintenance treatment of schizophrenia (1989) (0)
Brain volume correlated with neuropsychological ability in first episode schizophrenia (1995) (0)
Sensitization in the pathogenesis and natural history of schizophrenia (2002) (0)
Dr. Bilder and Colleagues Reply (2002) (0)
Ellen Stover (2014) (0)
Reviewers for Neuropsychiatric Disease and Treatment, Volume 1, 2005 (2006) (0)
APA 2014: Changing the Practice and Perception of Psychiatry (2014) (0)
Biochemical effects of clozapine in schizophrenia (1989) (0)
Pharmacogenetic dissection of central and peripheral candidate genes in atypical antipsychotic-induced weight-gain (2001) (0)
Delayed matching to sample in first episode schizophrenia (1995) (0)
Persecutory Delusions and the Transition from Clinical High-Risk to Syndromal Psychosis (2020) (0)
Politics of Psychiatry and Mental Health Care (2014) (0)
The Truth About Psychiatry and Health Care Insurance (2014) (0)
Lost In Translation: What We Really Learned From CATIE (2006) (0)
Books Received (2009) (0)
423 MRI landmark shape analysis of neuroanatomy in first-episode schizophrenia (1997) (0)
Dr. Keefe and Colleagues Reply. (2007) (0)
Dose occupancy relationship for a D1 agonist using [11C] NNC 112 in primates (2009) (0)
Author's reply (2012) (0)
IPS to Feature Patrick Kennedy, Celebrate Community Psychiatry (2013) (0)
[A genetic signature for complex psychiatric diseases]. (2010) (0)
The Many Clinical Phases of Early Psychosis and the Importance of Psychoeducation and Medication Management (2020) (0)
Raising the standard of care for schizophrenia is an achievable goal (2017) (0)
AOT and Long-Term Use of Antipsychotics. (2016) (0)
446 Parcellation of the frontal lobes in first-episode schizophrenia (1997) (0)
Psychedelic Drugs for Mental Disorders and Human Potential: Placebo or Panacea (2021) (0)
Antipsychotic Tn-DaIs in Schizophrenia The CA TI E Project (2016) (0)
Schizophrenia research series: from molecule to public policy. (1999) (0)
Violence in Schizophrenia (2020) (0)
72. Longitudinal neuropsychological change in first-episode schizophrenia (1996) (0)
Response to "Unrelated agranulocytosis in a patient taking clozapine". (1994) (0)
Essential Psychiatry: Biological treatments for psychotic disorders (2008) (0)
Cumulative sojourn time in longitudinal studies: a sequential imputation method to handle missing health state data due to dropout (2014) (0)
Dr. Volavka and Colleagues Reply (2003) (0)
50 Years After: Will We Realize JFK’s Vision for Mental Health Care? (2013) (0)
Personalized Medicine for Schizophrenia (2010) (0)
Early Detection of Schizophrenia: The Time Is Now (2013) (0)
Effectiveness and efficacy: Staying on treatment and symptom reduction (2010) (0)
Editorial (1995) (0)
Comparison of behavioral effects of olanzapine and clozapine in a genetic model of NMDA receptor hypofunction (2003) (0)
Abnormal brain morphology in MRI scans of first episode schizophrenics associated with poor treatment response (1990) (0)
Pathophysiology of Schizophrenia (2001) (0)
Behavioural effects of IV MCPP in schizophrenia (1993) (0)
A chronometric analysis of executive deficits in acute and stable phases of first episode schizophrenia (1993) (0)
Incidence and correlates of TD in first episode schizophrenia (1995) (0)
P.2.085 Amphetamine and stress-induced behaviors and c-Fos expression in a genetic model of NMDA receptor hypofunction (2003) (0)
Structure-function relations in first episode schizophrenia (1996) (0)
Prevention of relapse in schizophrenia Prof. A.C. Altamura. Department of Psychiatry, Istituto Scienze Biomediche, University of Milan, Ospedale L. Sacco, Via G.B. Grassi, 75-20175-Milano, Italy (1998) (0)
GENETIC ASSOCIATION ANALYSIS OF THE GFR ALPHA GENES WITH SCHIZOPHRENIA AND CLOZAPINE RESPONSE (2008) (0)
THE DEFINITION OF AN ATYPICAL ANTIPSYCHOTIC (1998) (0)
Visual working-memory dysfunction and P3 in schizophrenia (1995) (0)
59 POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN (2019) (0)
84. Clinical correlates of structural brain abnormalities in schizophrenia (2000) (0)
Medicine and the Mind. (2020) (0)
Psychiatric diagnosis: Exploration of biological predictors: Edited by Hagop S. Akiskal and William L. Webb. New York, S. P. Medical and Scientific Books, 1978 (1979) (0)
A genetic signature for complex psychiatric diseases (2010) (0)
Dysphoria associated with methylphenidate infusions. (1988) (0)
Clozapine and Treatment-Refractory Illness (2020) (0)
F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS (2018) (0)
Group therapy with schizophrenia patients. Authors' reply (2006) (0)
Effects of chronic treatment with typical and atypical antipsychotic drugs on the caudate nucleus in the rat (1996) (0)
149 Large or expanded CAG/CTG trinucleotide repeats as an etiological factor in schizophrenia (1997) (0)
Treatment of Schizophrenia: Current Capability, Future Promise (2012) (0)
Reduced mesiotemporal lobe volumes and asymmetries in schizophrenia (1995) (0)
EVIDENCE FOR SENSITIZATION IN EARLY STAGE OF SCHIZOPHRENIA (1992) (0)
SU86 VALIDATION STUDY IN TWO GENOME-WIDE SIGNIFICANT RISK VARIANTS FOR ANTIPSYCHOTIC INDUCED WEIGHT GAIN (2019) (0)
Biological predictors of antipsychotic treatment response (1996) (0)
Neurosteroid modulation of GABAergic neurotransmission in the central amygdala (2003) (0)
Clozapine: Comparative response and morbidity (1988) (0)
118. The Challenges of Testing D1 Agonists in Schizophrenia (2019) (0)
Clozapine response in chronic schizophrenia not associated with brain morphology on MRI: A preliminary report (1994) (0)
Quantitative features of eye movement dysfunctions in schizophrenics (1991) (0)
Interview: In search of the pathophysiology and prevention of schizophrenia (2011) (0)
PM389. Preliminary Genetic Model Predicting Clozapine Response (2016) (0)
Brain morphology, dopamine and outcome in first episode schizophrenia (1989) (0)
Interpreting the Results of the CATIE Study (2006) (0)
Ventricular Volumes In Patients With Temporal Lobe Epilepsy And Psychosis (1994) (0)
73. BCL-2 protein reduced in schizophrenic temporal cortex (2000) (0)
Clinical Phenomenology CHAIRPERSON (2005) (0)
257 Neuropsychological comparison of executive functions in first-episode schizophrenia and temporal lobe epilepsy (1997) (0)
Drs. Stroup, Rosenheck, Essock, and Lieberman Reply (2007) (0)
Dr Kantrowitz and Colleagues Reply. (2016) (0)
The Capgras Delusion (2020) (0)
F24SYSTEMS BIOLOGY APPROACH TO EVALUATE GENETIC FACTORS OF ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN PATIENTS WITH SCHIZOPHRENIA (2019) (0)
50. Ziprasidone blocks ketamine-induced brain metabolic activation (2000) (0)
Contents of the American Journal of Psychiatry (1995) (0)
Bibliography B IPOLAR D ISORDER (2011) (0)
Contents of the American Journal of Psychiatry (2004) (0)
Subject Index Vol. 24, 2002 (2003) (0)
100. Differential effects of typical and atypical antipsychotic medication on plasma prolactin levels (1996) (0)
Parkinsonism in neuroleptic naive schizophrenic patients (1995) (0)
70. Baseline and follow-up mesiotemporal volumes in first episode schizophrenics (1996) (0)
Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. (2006) (0)
Motor performance in schizophrenia: Treatment effects and predictive validity (1995) (0)
What is the nature of the eye movement dysfunctions found in schizophrenics? (1989) (0)
Anxiety Disorders: Foreword by Jeffrey A. Lieberman (2010) (0)
Alexander H Glassman (2011) (0)
Premature disinhibition of visual P3 in schizophrenia (1994) (0)
Limbic system morphology in schizophrenia: A comparison of new post mortem and MRI data (1991) (0)
No association between the COMT VAL158MET polymorphism and antipsychotic response in schizophrenia (2003) (0)
Clinical Trial of New Drug for Schizophrenia. Reply. (2021) (0)
Impaired Functioning and Downward Shift in Functioning in Schizophrenia (2020) (0)
PHARMACOGENETICS OF SCHIZOPHRENIA: TARDIVE DYSKINESIA AND WEIGHT GAIN (2008) (0)
Response to Kornfeld. (2015) (0)
FINDINGS OF PHASE 3 OF THE CATIE SCHIZOPHRENIA TRIAL (2008) (0)
The association of premorbid function in schizophrenia with baseline symptomatology, treatment response and medication side-effects (2001) (0)
Computerized neurocognitive assessment: Clinical trials and FMRI applications (2003) (0)
In Memoriam (2014) (0)
GLIAL CELL LINE–DERIVED NEUROTROPHIC FACTOR RECEPTOR ALPHA 2 IS ASSOCIATED WITH TARDIVE DYSKINESIA (2010) (0)
Neuromuscular effects of monoamine oxidase inhibitors. (1986) (0)
Jay Scully Deserves Our Thanks For a Job Well Done (2013) (0)
Time to onset of extrapyramidal symptoms in first episode of psychosis (1996) (0)
Pathophysiology in the clinical course of schizophrenia (1998) (0)
Drs. Lieberman and Rush Reply (1997) (0)
Neuroleptic-Induced Movement Disorders: Development of novel antipsychotic drugs with reduced extrapyramidal side effects (1996) (0)
Shrinks: The Untold Story of Psychiatry A Critical Discussion (2015) (0)
Collaborative Care: An Integral Part of Psychiatry’s Future (2013) (0)
M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN (2020) (0)
Predictors of Tardive Dyskinesia in First Episode Schizophrenia (1994) (0)
Duration of illness and treatment effects on Duration of illness and treatment effects on hippocampal volume in male patients with hippocampal volume in male patients with schizophrenia (2005) (0)
379. Symptom dimensions in first-episode schizophrenia: A longitudinal, confirmatory factor analytic study (1998) (0)
A 22-YEAR-OLD MALE WITH A MANIC EPISODE — (0)
Time to Re-Engage With Pharma? (2013) (0)
SU3. Preliminary Study for Association of Genome-Wide Significant Glutamate Receptor Schizophrenia Risk Variants With Clozapine Response (2017) (0)
Longitudinal course of brain morphology in first episode schizophrenia (1996) (0)
Ventricular shape of monozygotic twins discordant for schizophrenia reflects vulnerability (2003) (0)
F181. A Randomized, Single-Blind, Parallel-Group Study to Evaluate the Effects of TS-134 on Ketamine- Induced Bold Signals in Resting fMRI in Healthy Adult Subjects (2019) (0)
Electroconvulsive Therapy: A Potent Therapy for Major Depressive Disorder (2014) (0)
What It Means to Be President (2013) (0)
An analysis of motivating factors in 1,725 worldwide cases of mass murder between 1900-2019 (2023) (0)
Drug-Induced and Other Acute Psychoses in an Emergency-Room Setting (2020) (0)
Richard Resnick (2019) (0)
Change, Challenge, and Opportunity: Psychiatry Through the Looking Glass of Research (2013) (0)
Pharmacogenetics of antipsychotic induced weight gain and tardive dyskinesia (2000) (0)
The Role of Psychiatrists in the Brave New World of Health Care (2014) (0)
437. Language and superior temporal gyrus volumes in schizophrenia (1998) (0)
Comparative Efficacy and Effectiveness in the Drug Treatment of Schizophrenia (2011) (0)
Is frontal lobe dysfunction really generalized deficit in schizophrenia? (1994) (0)
The First-Episode of Psychosis and Suicide in Schizophrenia (2020) (0)
Will the Government Do the Right Thing (2013) (0)
Comprar Antipsychotic Trials in Schizophrenia | T. Scott Stroup | 9780521895330 | Cambridge University Press (2010) (0)
35. Neuropsychological prediction of functional outcome in first-episode schizophrenia (1998) (0)
Erratum: AKT1 and neurocognition in schizophrenia (Australian and New Zealand Journal of Psychiatry (2007) 41 (169-177)) (2009) (0)
Auditory Hallucinations and Religious Delusions (2020) (0)
145. Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors (2000) (0)
tardive dyskinesia. Spastic dysphonia and denervation signs in a young man with (2012) (0)
Questioning DST normalization as a guide to tricyclic discontinuation. (1983) (0)
Frontolimbic Mechanisms for Perceptual and Response Classification in Schizophrenia (1996) (0)
Briefs from the fields of Neurology & Neuropsychiatry (1998) (0)
T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA -- A FOLLOW-UP ON THE VALBENAZINE TARGET VMAT2/SLC18A2 (2018) (0)
Contents continued (2023) (0)
Drugs for Treating Substance Abuse Disorders (2006) (0)
394 Reduced anterior hippocampal volumes are associated with alternating response patterns in first episode schizophrenia (1997) (0)
Comprar Psychiatry, 2 Volume Set | Prof. Kian Fan Chung | 9780470065716 | Wiley (2008) (0)
Erratum: Rates of depressive and anxiety disorders in a residential mother-infant unit for unsettled infants (Australian and New Zealand Journal of Psychiatry (2007) 41 (836-842)) (2009) (0)
The Heritability of Schizophrenia and Dealing with Having a Family Member with Schizophrenia (2020) (0)
Sulcal volume and prominence in first episode schizophrenia (1994) (0)
WC1F SPI-A DIMENSIONS: OVERSTRAIN AND ITS RELATION TO STRESS REACTIVITY AND SOCIAL FUNCTION IN PRODROMAL PATIENTS (2006) (0)
The smartest person in the room: Donald F. Klein, M.D. (1928–2019) (2019) (0)
Contents Vol. 24, 2002 (2003) (0)
Change, Challenge, and Opportunity: Psychiatry in the Age of Health Care Reform (2013) (0)
P.3.d.051 Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies (2013) (0)
68-6 Atypical antipsychotic drug treatment in the early stages of schizophrenia (1997) (0)
P.1.a.002 Glial cell-derived neurotrophic family (GFR) alpha 1 receptor polymorphisms and weight change during clozapine treatment (2008) (0)
Cultivating the Next Generation of Psychiatrists (2014) (0)
Hiding in Plain Sight: The Public Health Crisis of Suicide (2014) (0)
S-9-4 Treatment and consequences of relapse in schizophrenia (1996) (0)
Understanding and Caring for People with Schizophrenia (2020) (0)
A Scientific Pioneer of Psychiatry. (2016) (0)
Molecular genetics of neurodevelopment and treatment response in psychosis (2003) (0)
Schizophrenia Outcomes Functioning Interview--Informant Version (2012) (0)
Behavioral neurochemistry: Jose M. R. Delgado and Francis V. DeFeudis (eds). Spectrum Publications, New York (1980) (0)
Superior temporal gyrus volume and asymmetry in first-episode schizophrenia (1995) (0)
454 Absence of overall cortical and subcortical volume differences among major mental disorders (1997) (0)
Schizophrenia Outcomes Functioning Interview--Patient Version (2012) (0)
Cognitive Enhancers and Treatments for Alzheimer's Disease (2006) (0)
Comparative effectiveness of antipsychotic drugs. Authors' reply (2003) (0)
Back to the Future: Psychiatry’s Re-Commitment to Public Mental Health (2017) (0)
Thank You for the Opportunity (2014) (0)
Antipsychotic Trials in Schizophrenia: Conclusion and implications for practice and policy (2010) (0)
Measuring outcome priorities and preferences Measuring outcome priorities and preferences in people with schizophrenia in people with schizophrenia (2005) (0)
Using Psychotherapy and Medications to Treat a Teenager with Prodromal Symptoms (2020) (0)
Cortical-subcortical dysconnectivity expressed by attenuated cortical c-fos induction by acute amphetamine treatment or acute swim stress in mice with reduced NMDA receptor1 expression (2003) (0)
273. Neuropsychological correlates of prefrontal volume in schizophrenia (1996) (0)
Antipsychotic Trials in Schizophrenia: Introduction (2010) (0)
Fixed-False Beliefs (2020) (0)
What CATIE Found: Results From the Schizophrenia Trial (2008) (0)
498. Chronic haloperidol administration significantly increases striatal volumes in the RAT (2000) (0)
378. Working memory deficits in schizophrenia persist after matching on task difficulty (1998) (0)
Illness Phase as a Key Assessment and Intervention Window for Psychosis (2022) (0)
Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS) (2018) (0)
UNRELATED AGRANULOCYTOSIS IN A PATIENT TAKING CLOZAPINE. AUTHOR'S REPLY (1994) (0)
Antipsychotic Drugs: the Current Limitations and Future Promises (1996) (0)
144. Cytokine regulation of embryonic cortical neuron survival: implications for schizophrenia (2000) (0)
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study. (2023) (0)
Medical Conditions That Can Masquerade as Schizophrenia (2020) (0)
VKučinskas-2001-2016 (2016) (0)
"It's Not What You Think: An Evolutionary Theory of Spiritual Enlightenment" (2011) (0)
48-1 Extrapyramidal signs in dyskinesia in first episode schizophrenia (1997) (0)
Antipsychotic Trials in Schizophrenia: Implications for research design and study implementation (2010) (0)
Front & Back Matter (2012) (0)
APA Successful in Attaining Higher Work Values for Psychiatry (2014) (0)
First-Episode Part II. Editors' Introduction (1992) (0)
The valid assessment and diagnosis of akathisia is of great importance for antipsychotic treatment and for the evaluation of the side-effects of neuroleptics (2006) (0)
We've come a long way. (2017) (0)
Gender differences in clozapine treated schizophrenic patients (1993) (0)

This paper list is powered by the following services:

Other Resources About Jeffrey Lieberman

What Schools Are Affiliated With Jeffrey Lieberman?

Jeffrey Lieberman is affiliated with the following schools:

Jeffrey Lieberman's Academic­Influence.com Rankings